RET and thyroid gland carcinoma: Additionally, the selpercatinib LIBRETTO-001 trial has also updated results in RET-fusion thyroid cancer, reaching an ORR of 79% and, again, a DCR of 100%, as well as a median duration of response of 18 months (95% CI: 7.6-NE).